Cargando…

DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity

RATIONALE: Consensus guidelines on the management of methotrexate-induced nephrotoxicity using glucarpidase (Voraxaze) may be relatively unfamiliar to the nephrology community. PRESENTING CONCERNS OF THE PATIENT: A 61-year-old man with intravascular large B-cell lymphoma was admitted for cycle #1 of...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Ann, Beriault, Daniel, Jung, Benjamin, Nikonova, Anna, Abosh, Dory, Lee, Samantha, Zaltzman, Jeff, Perl, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926974/
https://www.ncbi.nlm.nih.gov/pubmed/31903191
http://dx.doi.org/10.1177/2054358119895078
_version_ 1783482217944580096
author Young, Ann
Beriault, Daniel
Jung, Benjamin
Nikonova, Anna
Abosh, Dory
Lee, Samantha
Zaltzman, Jeff
Perl, Jeffrey
author_facet Young, Ann
Beriault, Daniel
Jung, Benjamin
Nikonova, Anna
Abosh, Dory
Lee, Samantha
Zaltzman, Jeff
Perl, Jeffrey
author_sort Young, Ann
collection PubMed
description RATIONALE: Consensus guidelines on the management of methotrexate-induced nephrotoxicity using glucarpidase (Voraxaze) may be relatively unfamiliar to the nephrology community. PRESENTING CONCERNS OF THE PATIENT: A 61-year-old man with intravascular large B-cell lymphoma was admitted for cycle #1 of high-dose methotrexate (HDMTX) following 2 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. On admission, he was clinically euvolemic and had a creatinine clearance of 98 mL/min. He received standard HDMTX toxicity prophylaxis with volume expansion, urinary alkalinization, and leucovorin rescue. DIAGNOSES: Despite prophylactic efforts, he developed a severe acute kidney injury, creatinine 63 to 226 µmol/L (2.56 mg/dL), following HDMTX, impaired methotrexate clearance, and neurotoxicity manifested by status epilepticus. INTERVENTIONS: He was given glucarpidase to convert extracellular methotrexate into its inactive metabolites, glutamate and DAMPA (4-deoxy-4-amino-N(10)-methylpteroic acid) at 52 hours post-HDMTX. Cross-reactivity between commercial methotrexate immunoassays with DAMPA led to falsely elevated methotrexate concentrations for much longer than expected based on the current guideline (5 days instead of <48 hours). This required ongoing monitoring of methotrexate concentration by mass spectrometry. OUTCOMES: The patient remained nonoliguric and did not develop acute indications for dialysis. Serum creatinine peaked at 608 µmol/L (6.88 mg/dL) 6 days after HDMTX. He ultimately had a full renal and neurologic recovery. LESSONS LEARNED: Glucarpidase is an effective option for nonrenal elimination of methotrexate-induced nephrotoxicity. Timing of methotrexate concentration monitoring to assess for toxicity, how to access the drug, and the need for ongoing monitoring by mass spectrometry beyond the guideline recommendation are highlighted for centers where HDMTX therapy may be used.
format Online
Article
Text
id pubmed-6926974
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-69269742020-01-03 DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity Young, Ann Beriault, Daniel Jung, Benjamin Nikonova, Anna Abosh, Dory Lee, Samantha Zaltzman, Jeff Perl, Jeffrey Can J Kidney Health Dis Educational Case Report RATIONALE: Consensus guidelines on the management of methotrexate-induced nephrotoxicity using glucarpidase (Voraxaze) may be relatively unfamiliar to the nephrology community. PRESENTING CONCERNS OF THE PATIENT: A 61-year-old man with intravascular large B-cell lymphoma was admitted for cycle #1 of high-dose methotrexate (HDMTX) following 2 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. On admission, he was clinically euvolemic and had a creatinine clearance of 98 mL/min. He received standard HDMTX toxicity prophylaxis with volume expansion, urinary alkalinization, and leucovorin rescue. DIAGNOSES: Despite prophylactic efforts, he developed a severe acute kidney injury, creatinine 63 to 226 µmol/L (2.56 mg/dL), following HDMTX, impaired methotrexate clearance, and neurotoxicity manifested by status epilepticus. INTERVENTIONS: He was given glucarpidase to convert extracellular methotrexate into its inactive metabolites, glutamate and DAMPA (4-deoxy-4-amino-N(10)-methylpteroic acid) at 52 hours post-HDMTX. Cross-reactivity between commercial methotrexate immunoassays with DAMPA led to falsely elevated methotrexate concentrations for much longer than expected based on the current guideline (5 days instead of <48 hours). This required ongoing monitoring of methotrexate concentration by mass spectrometry. OUTCOMES: The patient remained nonoliguric and did not develop acute indications for dialysis. Serum creatinine peaked at 608 µmol/L (6.88 mg/dL) 6 days after HDMTX. He ultimately had a full renal and neurologic recovery. LESSONS LEARNED: Glucarpidase is an effective option for nonrenal elimination of methotrexate-induced nephrotoxicity. Timing of methotrexate concentration monitoring to assess for toxicity, how to access the drug, and the need for ongoing monitoring by mass spectrometry beyond the guideline recommendation are highlighted for centers where HDMTX therapy may be used. SAGE Publications 2019-12-21 /pmc/articles/PMC6926974/ /pubmed/31903191 http://dx.doi.org/10.1177/2054358119895078 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Educational Case Report
Young, Ann
Beriault, Daniel
Jung, Benjamin
Nikonova, Anna
Abosh, Dory
Lee, Samantha
Zaltzman, Jeff
Perl, Jeffrey
DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity
title DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity
title_full DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity
title_fullStr DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity
title_full_unstemmed DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity
title_short DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity
title_sort dampaned methotrexate: a case report and review of the management of acute methotrexate toxicity
topic Educational Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926974/
https://www.ncbi.nlm.nih.gov/pubmed/31903191
http://dx.doi.org/10.1177/2054358119895078
work_keys_str_mv AT youngann dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT beriaultdaniel dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT jungbenjamin dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT nikonovaanna dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT aboshdory dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT leesamantha dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT zaltzmanjeff dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity
AT perljeffrey dampanedmethotrexateacasereportandreviewofthemanagementofacutemethotrexatetoxicity